Oxford's COVID-19 vaccine has shown a positive result in its initial trial. According to a report published in the British medical journal, The Lancet, the COVID-19 vaccine produced a dual immune response in people aged 18 to 55.Officially known as AZD1222, this COVID-19 vaccine candidate has been developed by the University of Oxford and British-Swedish pharmaceutial company AstraZeneca Plc.
The large-scale phase III human trials of Oxford COVID-19 vaccine has already started in Brazil.AstraZeneca has joined Serum Institute of India (SII), the world's largest vaccine manufacturers by number of doses produced and sold, to produce the potential vaccine.